International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 7.2.2020
banner-elderly-lady-relaxing.jpg
min-artwork-morten-lasskogen.jpg
Weekly Update: Science to the Rescue!
As we watch COVID-19 cases spiral out of control across the U.S., there is an emergency reality check: How do we flatten this upward curve? Fortunately, science can help produce evidence-based practices and can guide the country towards strategies that will reduce this pandemic, allow a sensible reopening, and help us achieve the best outcomes for patients with myeloma.
2020BlogButton.png
Webinar-PostASCO-2020-minute.jpg
Watch a Replay of the Post-ASCO / Post-EHA Webinar
Join IMF Chairman of the Board Dr. Brian G.M. Durie, IMF Chief Medical Officer Dr. Joseph Mikhael, and Michigan State University Clinician Dr. Craig Cole for a discussion about current trends in myeloma. These myeloma experts focus on research from the 2020 American Society of Clinical Oncology annual meeting and the 2020 European Hematology Association annual meeting, both of which were recently held online.
2020WatchNowButton.png
virtual-funrasier-screenshot.jpg
Watch This Video to Learn How to Organize a Virtual FUNraiser
Meet Tim. Tim wants to do a virtual fundraiser for myeloma research, but he needs a hand. So he contacts the International Myeloma Foundation to help out. In this fun video, Tim learns the steps to organize a virtual FUNraiser. Track Tim's fundraising journey and learn how you too can get involved to give to the myeloma community.
2020WatchNowButton.png
540x270Gavelscope.jpg
IMF Presents Letter in Favor of Cancer Patients' Access to Oral Chemotherapy Drugs
On June 26, 2020, the IMF led the Coalition to Improve Access to Cancer Care in writing a letter to Sen. Lamar Alexander (Chairman of the Health, Education, Labor, and Pensions Committee), requesting input on how to deal with future pandemics and releasing a white paper with basic recommendations. Oral drugs are covered differently by insurers, and patients pay more out of pocket for them. The IMF letter focused on highlighting the financial burden patients face, particularly those of patients being transitioned onto these drugs due to COVID-19. While high patient out-of-pocket costs for these drugs are problematic during normal times, COVID-19 has increased this issue exponentially. Click the link below to read the complete letter.
2020ReadNowButton.png
bdngrantcropped.jpg
Calling All Researchers: Submit Your Grant Applications 
The Brian D. Novis Research Grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2021 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline to receive the applications is Saturday, August 1, 2020. 
2020ButtonApplyNow.png
ADD-KRd-VRd-NDMM-650.jpg
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

What are the results from the ENDURANCE trial that compares KRd to VRd in newly diagnosed myeloma patients?
Watch Now
 
Clinical Trials

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)


Search the Myeloma Matrix 2.0

Smart Patients: Join the Conversation
Upcoming Events
Miracles for Myeloma
Virtual 5K Run/Walk/Bike

Hawaiian Vacation Raffle
Kailua-Kona, Hawaii

Hatfield Hike
Appalachian Trail

Click here to see all events
 

We Thank Our Sponsors:

Amgen, Bristol-Myers Squibb, Genentech, GSK, Sanofi-Genzyme, and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
2020ButtonDonateBurg.png
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma

www.myeloma.org
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page